Navigation Links
Clinical trial looks to improve pancreatic cancer survival rates
Date:2/12/2013

AUGUSTA, Ga.Researchers at Georgia Regents University Cancer Center are investigating a new avenue of treatment to help boost poor pancreatic cancer survival rates.

The treatment combines a standard chemotherapy drug with a monoclonal antibody that may help the immune system fight pancreatic cancer.

Every year, nearly 44,000 patients are diagnosed with pancreatic cancer and more than 37,000 die from the diseaseincluding well-known figures such as Patrick Swayze, Margaret Mead and Luciano Pavarotti.

Despite increased public attention, the disease remains one of the deadliest forms of cancer because it tends to be symptom-free at its earliestand most treatablestages. Overall five-year survival rates are a dismal 5.6 percent.

Patients treated with surgery typically see their cancers recur within about seven months. Coupling surgery with the chemotherapy drug Gemcitabine in eligible patients extends disease-free survival to a little over 13 months. Now, researchers are turning to combination therapies to improve these rates, coupling chemotherapy with drugs that enhance the immune system's ability to fight cancer.

"One of the reasons cancer can be so difficult to treat is the fact that the immune system often doesn't recognize tumor cells as cancer, or the tumors themselves express substances to suppress the immune system," said GRU Cancer Center Director Samir N. Khleif. "Immunotherapy is considered to be an important approach since it targets those specific substances in order to establish a more effective response against cancer."

Promise has already been shown in monoclonal antibodies that fight cancer's ability to evade the immune system, said Khleif, who is the principal investigator on a pilot study combining Gemcitabine with a monoclonal antibody called CT-011 in certain pancreatic cancer patients who have been treated with surgery.

In animal models, CT-011 has been shown to inhibit tumor growth and extend survival in melanoma, lung cancer, fibrosarcoma, leukemia/lymphoma and colorectal cancer. It works by shutting down cell production of a protein called PD1 and its related proteins. PD1, also known as programmed death 1, triggers immune suppression in cancer.

"One of the main causes for immune suppression in pancreatic cancer and other cancers is the elevated expression of these proteins in tumors and surrounding cells," said Khleif. "This is why our cancer center is taking a leading role in advancing clinical trials examining the effectiveness of combination therapieswhich are increasingly being recognized as a promising new avenue of treatment for cancer."


'/>"/>

Contact: Danielle Moores
dwongmoores@yahoo.com
706-496-5956
Georgia Health Sciences University
Source:Eurekalert  

Related medicine news :

1. First targeted nanomedicine to enter human clinical studies
2. Clinical insight improves treatment with new lung cancer drug
3. Clinical news alert from the American Academy of Orthopaedic Surgeons
4. NYU Langone experts present research, clinical advances at neurosurgeons meeting
5. Kroenke honored for outstanding contributions in clinical research training
6. Awards celebrate clinical research that can improve health and alleviate suffering
7. Association for Psychological Science, SAGE launch Clinical Psychological Science
8. URMC clinical trial tests new regimen for hypertension
9. Analysis Finds Clinical Trials Often Small, of Poor Quality
10. Automated insulin dosage titration system demonstrates positive clinical study results
11. Clinical news alert: Journal of the American Academy of Orthopaedic Surgeons May highlights
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Clinical trial looks to improve pancreatic cancer survival rates
(Date:12/7/2016)... ... December 07, 2016 , ... Kenall Manufacturing, a leader in sealed healthcare ... The MPCNGX is a multi-function, sealed, LED luminaire that meets the needs of everyone ... when it’s needed. , A 2’ x 4’ model features four modes: ...
(Date:12/7/2016)... (PRWEB) , ... December 07, 2016 , ... ... a women growing up with a schizophrenic mother in a unique, personal perspective ... who specializes in treating trauma and addictive disorders at her private psychotherapy practice. ...
(Date:12/7/2016)... Valley, CA (PRWEB) , ... December 07, 2016 , ... ... be used in several ways to restore a more youthful appearance to the face. ... now offer Sculptra, along with a variety of other treatments, to rejuvenate and renew ...
(Date:12/7/2016)... (PRWEB) , ... December 07, 2016 , ... When it came time to blow out ... Just 40 minutes later, the Pediatric Heart Transplant team at Joe DiMaggio Children’s ... the Weston teen the hospital’s 30th heart transplant recipient. , “He was playing at ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... planning services to families and business owners in the greater Dallas metropolitan area, ... the Dallas Fallen Officer Foundation. , Established in 2009 by active police professionals ...
Breaking Medicine News(10 mins):
(Date:12/7/2016)... Dec. 7, 2016 Global Pulmonary ... drugs studies the current as well as future ... this report include companies and intermediaries engaged in ... and/or drug-device combinations as well as new entrants ... an elaborate executive summary along with a market ...
(Date:12/7/2016)... Diplomat Pharmacy, Inc. (NYSE: DPLO) has launched Diplomat Specialty ... IV Infusion Professional, BioRx, MedPro Rx, and XAS Infusion Suites. ... diplomat.is/specialty-infusion .  ... Diplomat Specialty Pharmacy (PRNewsFoto/Diplomat Pharmacy, Inc.) ... "As we continue to build on the work we have ...
(Date:12/7/2016)... ALTO, Calif. , Dec. 7, 2016  Varian ... an update to its previously announced plans to separate ... be executed via a tax-free distribution to Varian stockholders ... stand-alone public company that will hold the Imaging Components ... expected to be executed by the end of January ...
Breaking Medicine Technology: